Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diacetoxyscirpenol is a **type A trichothecene mycotoxin**, primarily produced by *Fusarium* fungi, and is part of a group of potent cytotoxins structurally characterized by a tricyclic sesquiterpenoid epoxide[1][5][6]. Trichothecene mycotoxins, including diacetoxyscirpenol, act as **potent inhibitors of protein synthesis**: they cross the plasma membrane and bind to ribosomes, disrupting the active site of peptidyl transferase in the large 28S ribosomal RNA[1][6]. This blocks the initiation, elongation, and termination phases of protein synthesis, leading to cell cycle disruption, apoptosis, ribotoxic stress responses, inhibition of DNA and RNA synthesis, and heightened oxidative stress[1][6]. As a result, diacetoxyscirpenol is cytotoxic to most eukaryotic cells, particularly those that are rapidly dividing, and has been studied as both an immunosuppressant and a potential anticancer agent (especially in clinical trials for leukemia and colorectal tumors, mostly discontinued before the late 1980s)[6]. It is known for its **extreme toxicity** by ingestion, inhalation, or parenteral administration, with noted effects including muscle weakness, nausea, vomiting, fever, and teratogenicity[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diacetoxyscirpenol.